Fresh analysis indicates that individuals who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who end traditional diet and exercise regimens.
Published data in a prominent medical journal points out that while obese individuals can lose substantial amounts of their total mass while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month once they quit.
"Individuals using such drugs need to be cognizant of the risk of fast weight regain when the treatment ends," stated researcher Dr. Susan Jebb.
That rate of regain means a return to starting mass within about one and a half years.
Comparing Treatments
The study, which reviewed dozens of studies involving thousands of patients, compared the effects of GLP-1 agonists with other pills.
The team note that people who shed pounds through dieting generally have a less rapid weight regain—perhaps 100 grams monthly—after stopping.
The Reason for the Fast Rebound
Nutrition scientists suggest the mode of action of the jabs is key to understanding the amplified regain.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Sustained high doses of the hormone levels several times higher than the body's typical production might result in the system to produce less of its own natural GLP-1, and could diminish sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this hormone supplement results in hunger is uncontrolled, making excessive eating much more probable."
A Chronic Disease?
Medical guidelines advise the jabs for individuals with weight-linked health risks, alongside recommended diet and exercise modifications.
Professionals contend that, considering the significant potential of weight regain, the treatment might need to be life-long.
This view is echoed by drug manufacturers, who state that the findings "emphasize the chronic nature of excess weight," similar to managing diseases like diabetes.
User Accounts
Users who have stopped the jabs explain a sudden resurgence of appetite.
"I experienced a trigger activating and you become ravenous," said a patient.
This challenge is exacerbated if individuals have not developed permanent lifestyle or habit modifications during therapy.
Growing Adoption
Figures suggest that a significant number of people in the UK have used these injections in the last 12 months, with desire continuing to grow.
- Use is higher among females than males.
- The 40s and 50s age group shows the greatest usage rates.
- Many obtain the drugs through private healthcare rather than the NHS.
Ultimately, clinicians emphasize that while these medications are potent tools for weight loss, they are not a magic solution and lasting health benefits relies on integrated behavioural management.
